Psychiatric NP Scope of Practice for Narcolepsy in Florida

If you’re a psychiatrist or PMHNP treating narcolepsy remotely, you’re operating in one of the most complicated regulatory environments in medicine. You’re prescribing Schedule II stimulants and other controlled substances via telehealth — which puts you at the intersection of DEA rules, state medical boards, pharmacy laws, and evolving telemedicine policy.

The good news? As of early 2026, you can prescribe narcolepsy medications via telehealth in most states, thanks to federal COVID-era flexibilities that have been extended through December 31, 2026. The bad news? That’s a temporary arrangement, state laws vary wildly, and if you’re a PMHNP, your authority to prescribe stimulants depends heavily on where you’re licensed.

This guide breaks down the current federal DEA rules, state-by-state telehealth prescribing laws, and scope-of-practice differences between psychiatrists and PMHNPs for narcolepsy treatment. Whether you’re considering joining a telehealth platform or just trying to stay compliant, here’s what you need to know.

Federal DEA Rules: The Ryan Haight Act and COVID-Era Flexibilities

The Law You’re Working Around (For Now)

The Ryan Haight Online Pharmacy Act of 2008 is the federal law governing controlled substance prescribing via the internet. It requires at least one in-person medical evaluation before a practitioner can prescribe any controlled substance via telemedicine (www.law.cornell.edu).

For narcolepsy providers, this is a problem. Most narcolepsy medications are controlled substances:

• Schedule II stimulants (methylphenidate, amphetamine salts, dextroamphetamine)
• Schedule IV wakefulness agents (modafinil, armodafinil)
• Schedule III sodium oxybate (Xyrem, with FDA REMS requirements)

Under strict Ryan Haight rules, you’d need to see every new narcolepsy patient in person before prescribing Adderall or modafinil. For a telehealth practice, that’s a dealbreaker.

The COVID Exception That’s Still Alive

In March 2020, the DEA waived the in-person requirement for the duration of the COVID-19 Public Health Emergency. When the PHE officially ended in May 2023, the DEA kept extending the telehealth flexibilities rather than cut off access to millions of patients.

As of January 2, 2026, the DEA and HHS announced a fourth extension of telehealth prescribing flexibilities through December 31, 2026 (www.hhs.gov).

What This Means for You:

• You can initiate and continue controlled substance prescriptions (including Schedule II stimulants) via telehealth without an in-person visit through the end of 2026
• Standard prescribing requirements still apply: you must be DEA-registered, licensed in the patient’s state, and prescribing for a legitimate medical purpose
• You must comply with state prescription monitoring program (PDMP) requirements
• Electronic prescribing mandates still apply

The Permanent Rules That Aren’t Here Yet

The DEA proposed permanent telemedicine rules in early 2023 that would have severely restricted controlled substance prescribing via telehealth — including requiring in-person visits after an initial 30-day supply for Schedule II drugs. After receiving over 38,000 public comments (mostly negative), the DEA shelved those proposals and went back to the drawing board (www.dea.gov).

As of February 2026, the only finalized telehealth rules are narrow exceptions for:

• Buprenorphine prescribing for opioid use disorder
• VA system patients (continuity of care provisions)

For narcolepsy, you’re still operating under the temporary extension. Providers should expect new proposed rules in late 2026, possibly with more flexibility than the original proposal — but nothing is certain.

Risk Management Under the Waiver

Even though telehealth prescribing is currently allowed, you still need to meet the standard of care:

• Conduct a thorough evaluation via video (or audio-only if your state permits and the clinical situation warrants)
• Document clinical rationale for controlled medications
• Use validated tools (Epworth Sleepiness Scale, sleep logs)
• Arrange for necessary diagnostic testing (polysomnography, MSLT) — even if you can’t order it directly, coordinate referrals
• Check your state’s PDMP before prescribing
• Schedule appropriate follow-ups to monitor efficacy and side effects

This isn’t just good medicine — it’s your defense if you’re ever audited or if a board complaint is filed.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State-by-State Telehealth Prescribing Laws for Narcolepsy

Federal DEA rules set the floor, but states can impose additional restrictions. Here’s how the six key states handle telehealth prescribing of controlled substances for narcolepsy:

Florida: The Outlier State

Florida has the most restrictive telehealth prescribing law for narcolepsy.

The Problem: Florida statute 456.47 explicitly prohibits prescribing Schedule II controlled substances via telehealth except for:

• Treating a psychiatric disorder
• Inpatient hospital care
• Hospice or nursing home patients

(www.leg.state.fl.us)

Narcolepsy is a sleep disorder, not a psychiatric disorder. This means a Florida-licensed provider cannot legally prescribe Adderall or other Schedule II stimulants via telehealth for narcolepsy, even under the federal DEA waiver.

Your Options in Florida:

• Prescribe modafinil or armodafinil (Schedule IV) via telehealth — these are not banned
• Require at least one in-person visit to initiate Schedule II stimulants, then manage via telehealth
• Partner with a brick-and-mortar clinic for the initial visit
• Focus on non-stimulant options for remote patients

Florida also restricts APRN prescribing: PMHNPs can only prescribe Schedule II drugs for a 7-day supply unless they’re a certified ‘psychiatric nurse’ treating a mental health condition (www.flsenate.gov). For narcolepsy, that 7-day limit applies, effectively requiring physician involvement for ongoing care.

New York: Aligned with Federal Rules

New York finalized new controlled substance prescribing regulations in May 2025 that require an in-person exam before prescribing controlled substances via telehealth — unless one of several exceptions applies (www.nixonpeabody.com).

The Key Exception: If you’re complying with applicable federal law (currently the DEA waiver), you can prescribe via telehealth without an in-person visit (www.nixonpeabody.com).

What This Means:

• As of 2026, you can prescribe narcolepsy medications via telehealth in New York under the DEA waiver
• If the DEA waiver expires and requires in-person exams, New York’s requirement will automatically kick in (unless you use one of the other exceptions, like a recent exam by a referring provider)
• You must check the I-STOP PDMP before every controlled substance prescription
• Electronic prescribing is mandatory

Texas: Video Required, But Otherwise Permissive

Texas allows controlled substance prescribing via telehealth as long as you follow standard of care and state technology requirements.

Key Requirements:

• You must use two-way audio and video (live video call). An audio-only phone call does not meet Texas standards for prescribing controlled substances
• Texas prohibits telehealth prescribing of controlled substances for chronic pain management (defined as >90 days), but this doesn’t apply to narcolepsy stimulants (www.cchpca.org)
• You must check the Texas PDMP before prescribing

APRN Restrictions: Texas does not allow APRNs to prescribe Schedule II controlled substances outside of hospital inpatient or hospice settings (www.tmb.state.tx.us). A Texas PMHNP cannot prescribe Adderall for narcolepsy in an outpatient telehealth setting — period. The supervising physician would have to write those prescriptions.

California: Full NP Authority Phased In

California has no additional state restrictions on telehealth prescribing of controlled substances beyond federal law. A telehealth exam is treated the same as in-person if the standard of care is met.

NP Authority: California’s AB 890 (implemented starting 2023) allows experienced NPs (≥4,600 hours or ~3 years of practice) to practice independently, including prescribing Schedule II–V controlled substances (rxagent.co). NPs must complete required pharmacology training on controlled substances and obtain a furnishing number with Schedule II authority (rn.ca.gov).

PDMP: You must check the CURES PDMP before prescribing Schedule II–IV for the first time and at least every 4 months for ongoing therapy.

Pennsylvania: Physician Collaboration Required

Pennsylvania allows telehealth prescribing under the same standard-of-care requirements as in-person care. There are no specific state-level bans on controlled substances via telemedicine.

APRN Scope: Pennsylvania is a restricted practice state. Certified Registered Nurse Practitioners (CRNPs) must have a collaborative agreement with a physician. They can prescribe Schedule II–V if the agreement permits, but:

• Schedule II prescriptions are limited to a 30-day supply
• Longer-term Schedule II therapy requires physician consultation
• The collaborating physician’s specialty should align with the CRNP’s practice

Pennsylvania recently removed the 72-hour initial limit on CRNP Schedule II prescribing, aligning with the 30-day standard.

Illinois: Full Practice Authority with Experience

Illinois allows telehealth prescribing of controlled substances following federal law. No additional state restrictions.

NP Authority: Illinois grants full practice authority to NPs who complete 4,000 hours of clinical practice under collaboration plus 250 hours of continuing education (rxagent.co). Once granted FPA, NPs can prescribe Schedule II–V independently (with a state mid-level controlled substance license in addition to DEA registration).

Caveat: Illinois law requires NPs with FPA to maintain a ‘consultation relationship’ with a physician when prescribing benzodiazepines or opioids. This likely does not apply to stimulants for narcolepsy, but the law isn’t entirely clear.

PDMP: Illinois mandates checking the ILPMP before prescribing controlled substances. Electronic prescribing is required as of 2023.

Psychiatrist vs PMHNP Scope of Practice for Narcolepsy

Psychiatrists: Full Authority, Everywhere

Psychiatrists (MD/DO) have unrestricted authority to diagnose and treat narcolepsy in all 50 states, assuming they:

• Hold an active medical license in the patient’s state
• Have a DEA registration with Schedule II authority
• Practice within their competency (which may involve coordinating sleep studies or consulting with sleep specialists)

Practical Reality: Most psychiatrists treating narcolepsy remotely will refer patients for diagnostic testing (polysomnography, MSLT) to confirm the diagnosis before long-term stimulant therapy. This can be done via local sleep centers, even if the ongoing medication management is telehealth.

PMHNPs: State-Dependent Authority

PMHNPs face a patchwork of state rules that directly impact their ability to manage narcolepsy independently.

Full Practice Authority States (California, New York, Illinois)

In these states, experienced PMHNPs can diagnose narcolepsy and prescribe all necessary medications (including Schedule II stimulants) without physician oversight.

California: NPs with 4,600+ hours and Schedule II furnishing authority can practice independently starting 2023 (rxagent.co).

New York: NPs with 3,600+ hours can practice independently (as of 2022, made permanent) (www.rivkinrounds.com).

Illinois: NPs meeting FPA criteria (4,000 hours + training) can prescribe independently, including Schedule II drugs.

Restricted Practice States (Texas, Florida, Pennsylvania)

In these states, PMHNPs need physician collaboration and face additional prescribing limits.

Texas: APRNs cannot prescribe Schedule II at all in outpatient settings (www.tmb.state.tx.us). The supervising physician must write all stimulant prescriptions. This makes independent PMHNP-led narcolepsy care impossible in Texas.

Florida: PMHNPs can prescribe Schedule II for only a 7-day supply unless they’re a certified ‘psychiatric nurse’ treating a mental health disorder (www.flsenate.gov). Since narcolepsy isn’t psychiatric, the 7-day limit applies — physician involvement is needed for refills.

Pennsylvania: CRNPs can prescribe Schedule II under physician collaboration, but only 30-day supplies initially, with physician consultation required for ongoing therapy.

The Economics of Narcolepsy Telehealth: Why Platforms Like Klarity Make Sense

Building a telehealth practice to treat narcolepsy is legally complex — but it’s also economically challenging if you’re doing it alone.

The DIY Marketing Reality

If you try to acquire narcolepsy patients on your own through SEO, Google Ads, or directory listings, here’s what you’re actually looking at:

SEO: Takes 6–12 months of consistent investment before generating meaningful patient flow. You need expertise in healthcare SEO, ongoing content creation, backlink building, and technical optimization. Most solo providers don’t have the time or knowledge.

Google Ads: Mental health keywords cost $15–40+ per click. Most clicks don’t convert to booked patients. Realistic cost per booked patient through PPC: $200–400+ when you factor in testing, optimization, and no-shows.

Directory Listings: Psychology Today and Zocdoc charge monthly fees ($30–100+/month for PT, booking fees for Zocdoc). You’re competing with hundreds of other providers on the same page. Total monthly cost including subscription fees adds up fast.

True Cost of Patient Acquisition: When you factor in agency/consultant fees, ad spend, staff time to handle leads, failed campaigns, and the months of investment before results, acquiring a qualified psychiatric patient typically costs $200–500+. And that’s if you know what you’re doing.

The Klarity Health Model: Pay-Per-Qualified-Patient

Klarity Health uses a pay-per-appointment model similar to Zocdoc, but with critical differences:

• No upfront marketing spend or monthly subscription fees
• Pre-qualified patients already matched to your specialty and availability
• No wasted ad spend on clicks that don’t convert
• Built-in telehealth infrastructure (no separate platform costs)
• Both insurance and cash-pay patient flow
• You control your schedule — only pay when you see patients

The Economic Case: Instead of spending $3,000–5,000/month on marketing with uncertain results, you pay a standard listing fee only when a qualified patient books with you. That’s guaranteed ROI vs gambling on marketing channels that may or may not work.

For providers starting out or scaling, a platform that handles patient acquisition removes the risk entirely. You focus on clinical care; the platform handles marketing, patient matching, credentialing support, and telehealth infrastructure.

Key Considerations for Narcolepsy Providers on Telehealth Platforms

Multi-State Licensing Strategy

Narcolepsy is rare (affecting ~1 in 2,000 people), so expanding your geographic reach is critical for building volume. Consider:

• Interstate Medical Licensure Compact (IMLC): Illinois, Texas, and Pennsylvania are members, making it easier to get licensed across member states. New York, Florida, and California are not in the IMLC.
• Priority states: Focus on high-population states with favorable regulations (California, New York, Illinois) if you’re a PMHNP with full practice authority

Diagnostic Testing Coordination

Confirming narcolepsy typically requires:

• Overnight polysomnography (to rule out sleep apnea)
• Multiple Sleep Latency Test (MSLT)

These must be done in person. Build referral relationships with local sleep centers in states where you practice, or partner with a platform that can coordinate testing.

REMS and Special Medications

Sodium oxybate (Xyrem, Xywav) is Schedule III but has FDA-mandated REMS (Risk Evaluation and Mitigation Strategy) requirements. You must enroll in the REMS program to prescribe it. This adds administrative overhead but is manageable if you treat enough narcolepsy patients.

Documentation Standards

Given the controlled substance nature of narcolepsy medications, meticulous documentation is critical:

• Objective evidence of excessive daytime sleepiness (Epworth score, sleep logs)
• Results of diagnostic testing (or referral documentation if coordinating)
• Clinical rationale for specific medication choices
• Risk-benefit discussion (stimulant abuse potential, side effects)
• PDMP checks (before each prescription)
• Monitoring plan (follow-up schedule, titration protocol)

Preparing for Post-2026 DEA Rules

When the temporary telehealth flexibilities expire (or new permanent rules are finalized), you may need to:

• Require an initial in-person visit for new patients starting Schedule II stimulants
• Partner with local clinics for physical exams
• Use a hybrid model (telehealth for ongoing management, in-person for initiation)
• Focus on states with telemedicine-friendly permanent rules

Watch for DEA announcements throughout 2026. The agency is expected to propose revised rules that may be more flexible than the original 2023 proposal, but nothing is guaranteed.

FAQ: Narcolepsy Telehealth Prescribing

Can I prescribe Adderall for narcolepsy via telehealth in 2026?

Yes, in most states — thanks to the DEA’s extended telehealth flexibilities through December 31, 2026. Exception: Florida prohibits Schedule II stimulant prescribing via telehealth for narcolepsy (it’s only allowed for psychiatric disorders).

Do I need to see narcolepsy patients in person before prescribing stimulants?

Not currently, under the federal DEA waiver. However, state law may require it (Florida does for Schedule II stimulants in narcolepsy). When the DEA waiver expires, you’ll likely need at least one in-person visit unless new permanent rules provide exceptions.

Can a PMHNP independently manage narcolepsy patients?

It depends on the state:

• Yes, independently: California (with experience/certification), New York (3,600+ hours), Illinois (with FPA)
• With physician collaboration: Pennsylvania (30-day Schedule II limit)
• Physician required for stimulants: Texas (APRNs can’t prescribe Schedule II outpatient), Florida (7-day limit unless psychiatric indication)

What diagnostic tests are required for narcolepsy?

Clinical diagnosis typically requires polysomnography (overnight sleep study) and MSLT (Multiple Sleep Latency Test). These must be done in person. If you’re practicing via telehealth, coordinate referrals to local sleep centers in the patient’s state.

Do I have to check the state PDMP every time I prescribe?

Yes. Every state requires PDMP checks before prescribing controlled substances. Frequency varies (some states require it for each prescription, others allow checking every 3–4 months for established patients). Check your state’s specific requirements.

What happens when the DEA telehealth waiver expires?

The current extension runs through December 31, 2026. The DEA is expected to propose new permanent rules in late 2026. Likely outcomes:

• Some form of in-person exam requirement (possibly just for initial prescriptions)
• Potential 30-day initial supply limits for Schedule II drugs
• Possible condition-specific exceptions (like the finalized buprenorphine rules)

Monitor DEA announcements closely and be prepared to adjust your practice model.

Can I use audio-only (phone) visits to prescribe narcolepsy medications?

State laws vary:

• Texas requires video for prescribing controlled substances
• Most other states allow audio-only if clinically appropriate and standard of care is met
• Under the current DEA waiver, audio-only is technically permitted federally, but check your state board guidance

Best practice: Use video for initial evaluations and when prescribing controlled substances.

Next Steps: Joining a Telehealth Platform That Handles the Complexity

If you’re a psychiatrist or PMHNP looking to treat narcolepsy patients remotely, you’re facing:

• Evolving federal DEA rules
• Conflicting state telehealth laws
• Multi-state licensing requirements
• Complex patient acquisition economics
• Administrative burden of PDMP checks, e-prescribing, and documentation

Platforms like Klarity Health remove most of that friction:

• Pre-qualified patient flow matched to your specialty (no wasted marketing spend)
• Multi-state credentialing support (helping you get licensed where demand is highest)
• Built-in compliance infrastructure (PDMP integration, e-prescribing, documentation templates)
• Pay-per-patient model (only pay when a qualified patient books — no upfront marketing risk)

Instead of gambling thousands of dollars per month on SEO or Google Ads that may not work, you pay a standard listing fee only when you see patients. That’s guaranteed ROI.

Ready to explore a smarter way to build your narcolepsy practice? Learn more about joining Klarity Health’s provider network and start seeing patients without the marketing headaches.

References

1. HHS Press Release – ‘HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026’ (January 2, 2026). www.hhs.gov

2. DEA Press Release – ‘DEA Extends Telemedicine Flexibilities to Ensure Continued Access to Care’ (December 31, 2025). www.dea.gov

3. 21 U.S.C. §829(e) – Ryan Haight Act definitions (in-person medical evaluation requirements). Legal Information Institute, Cornell University. www.law.cornell.edu

4. Nixon Peabody Legal Alert – ‘New York State Finalizes Telemedicine Rule for Controlled Substances’ (June 18, 2025). www.nixonpeabody.com

5. Florida Statutes §456.47 – Use of Telehealth to Provide Services (restrictions on Schedule II prescribing via telehealth). Florida Legislature. www.leg.state.fl.us

Source:

• https://www.law.cornell.edu/definitions/uscode.php?defid=21-USC-1796173870-113781527&height=800&iframe=true&termoccur=999&term_src=title%3A21%3Achapter%3A13%3Asubchapter%3AI%3Apart%3AC%3Asection%3A831&width=840#:~:text=,that%20a%20prescription%20has%20been
• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,while%20permanent%20rules%20are%20finalized
• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=promulgate%20a%20final%20set%20of,Medications%2C%E2%80%9D%20was%20submitted%20to%20the
• https://www.dea.gov/press-releases/2025/12/31/dea-extends-telemedicine-flexibilities-ensure-continued-access-care#:~:text=On%20January%2017%2C%202025%2C%20DEA,to%20as%20the%20%E2%80%9CTwo%20Final
• https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499%2F0456%2FSections%2F0456.47.html#:~:text=telehealth%20to%20provide%20health%20care,in%20Schedule%20II%20of%20s
• https://www.tmb.state.tx.us/page/facility-based-prescriptive-delegation#:~:text=at%20the%20hospital%E2%80%99s%20facility,from%20a%20qualified%20hospice%20provider
• https://www.cchpca.org/resources/state-telehealth-laws-and-reimbursement-policies-report-fall-2025/#:~:text=Texas%20regulations%20emphasize%20continuity%20of,Note
• https://www.nixonpeabody.com/insights/alerts/2025/06/18/new-york-state-finalizes-telemedicine-rule-for-controlled-substances#:~:text=match%20at%20L114%20The%20rule,and%20the%20US%20Department%20of
• https://www.nixonpeabody.com/insights/alerts/2025/06/18/new-york-state-finalizes-telemedicine-rule-for-controlled-substances#:~:text=In%20short%2C%20the%20exception%20permits,as%20a%20condition%20of%20state
• https://rxagent.co/blog/np-prescribing-authority#:~:text=Conversely%2C%20in%20Restricted%20Practice%20states,expand%20this%20scope%20%206